UV-B-induced damage to the lens in vitro: prevention by caffeine.
Ultraviolet (UV) irradiation is one of the significant risk factors in the genesis of cataracts. Pathogenetically, the process can be triggered by the intraocular generation of various reactive species of oxygen that are well known to be initiated by the penetration of light, especially of the UV frequencies. The contribution of UV exposure in the etiology of this disease is likely to increase further due to ozone depletion in the upper atmosphere. The present studies were undertaken to examine if the UV effects can be attenuated with the xanthine-based alkaloids primarily present in tea and coffee. We have examined this possibility by in vitro lens culture studies with caffeine. As expected, mice lenses incubated in Tyrode solution exposed to UV at 302 nm are physiologically damaged, as evidenced by the inhibition of the active transport of (86)Rb(+), an ion acting as a surrogate of the K(+). There was a simultaneous decrease in the levels of adenosine triphosphate and glutathione. The addition of caffeine to the medium prevented such deleterious effects. That caffeine and perhaps other xanthinoids have a protective effect against cataract formation induced by UV has hence been demonstrated for the first time.
Varma
Shambhu D
SD
Department of Ophthalmology and Visual Sciences, University of Maryland School of Medicine, Baltimore, MD 21201, USA. svarm001@umaryland.edu
Hegde
Kavita R
KR
Kovtun
Svitlana
S
D000255:Adenosine Triphosphate / Q000378:metabolism; D000818:Animals; D001693:Biological Transport, Active; D002110:Caffeine / Q000627:therapeutic use*; D002386:Cataract / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control*; D005978:Glutathione / Q000378:metabolism; D066298:In Vitro Techniques; D007908:Lens, Crystalline / Q000187:drug effects / Q000378:metabolism / Q000528:radiation effects*; D051379:Mice; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D011833:Radiation Injuries, Experimental / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control; D017382:Reactive Oxygen Species / Q000378:metabolism; D012414:Rubidium Radioisotopes; D014466:Ultraviolet Rays / Q000009:adverse effects*
D010726:Phosphodiesterase Inhibitors; D017382:Reactive Oxygen Species; D012414:Rubidium Radioisotopes; D002110:Caffeine; D000255:Adenosine Triphosphate; D005978:Glutathione
Invest Ophthalmol. 1970 Aug;9(8):629-38
5456505
Ophthalmic Res. 2004 Sep-Oct;36(5):264-9
15583432
Curr Eye Res. 1995 Aug;14(8):643-9
8529399
Methods Biochem Anal. 1954;1:341-56
13193535
Ophthalmology. 2008 Apr;115(4):597-8
18387405
Br J Ophthalmol. 1982 Jan;66(1):35-42
7055541
Am J Ophthalmol. 2001 Jul;132(1):19-26
11438049
J Ocul Pharmacol Ther. 2007 Oct;23(5):492-502
17900232
N Engl J Med. 1988 Dec 1;319(22):1429-33
3185661
Food Chem Toxicol. 1991 Jan;29(1):1-6
1847890
Ophthalmic Res. 2002 Jul-Aug;34(4):258-63
12297700
Arch Biochem Biophys. 1959 May;82(1):70-7
13650640
Curr Eye Res. 1984 Jan;3(1):59-65
6690229
Mol Cell Biochem. 2004 Nov;266(1-2):37-56
15646026
JAMA. 1998 Aug 26;280(8):714-8
9728643
Ophthalmology. 2008 Apr;115(4):599-607.e1
18387406
Biochim Biophys Acta. 2003 Jun 11;1621(3):246-52
12787921
Curr Eye Res. 1984 Jan;3(1):35-57
6360540
Curr Eye Res. 1984 Jan;3(1):145-50
6690217
Exp Eye Res. 1990 Jun;50(6):805-12
2373172